Nasdaq confirms compliance with Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above $1.00; minimum bid price matter is closed

JERUSALEM, Sept. 21, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company combining innovative immunology therapeutic development with a revenue-generating contract development and manufacturing organization ("CDMO"), today announced that it has received written notification from Nasdaq Listing Qualifications confirming that the Company has regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and that the matter is now closed.

On March 12, 2026, Nasdaq Staff notified Scinai that the Company's American Depositary Shares ("ADSs") had failed to maintain a minimum bid price of $1.00 over the prior 30 consecutive business days. In its September 18, 2026 compliance letter, Nasdaq stated that for the 19 consecutive business days from August 21, 2026 through September 17, 2026, the closing bid price of Scinai's ADSs was at $1.00 per share or greater. Accordingly, Nasdaq determined that Scinai had regained compliance with Listing Rule 5550(a)(2).

"Receiving Nasdaq's confirmation closes an important compliance matter for Scinai," said Amir Reichman, Chief Executive Officer of Scinai. "We appreciate Nasdaq Staff's review and constructive engagement throughout the process. With this matter resolved, our focus remains on commercial execution at Scinai Biopharma Services and disciplined advancement of our NanoAb programs."

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on the development of innovative immunology therapies and the operation of a contract development and manufacturing organization. The Company is developing its NanoAb platform through research collaboration and license arrangements with the Max Planck Society and University Medical Center Göttingen.

Scinai also owns Scinai Biopharma Services Ltd., a CDMO providing development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel.

For more information, please visit www.scinai.com.

Company Contacts

Business Development | +972 8 930 2529 | [email protected]

Investor Relations, Allele Capital Partners | +1 (561) 388-8178 | [email protected]

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws. These include statements regarding the Company's continued commercial execution, CDMO growth and customer programs, NanoAb development and the Company's ability to maintain compliance with Nasdaq listing requirements.

These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Such risks include the Company's ability to secure sufficient financing or non-dilutive funding on satisfactory terms or at all; increase CDMO revenues and execute customer programs; maintain research and license arrangements; generate supportive preclinical or clinical data; obtain regulatory approvals; secure development partners; maintain compliance with Nasdaq listing requirements; and respond to competition and market, regulatory, geopolitical and economic conditions. Additional information appears in the Company's filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F filed on April 1, 2026. Forward-looking statements speak only as of the date of this press release. Except as required by law, the Company undertakes no obligation to update or revise them.

SOURCE SCINAI IMMUNOTHERAPEUTICS LTD

Share this article

—sNDA Under Review for Full Approval Is Based on Positive Results From Phase 3b ENCORE Study—

—Full Approval Could Bring ARIKAYCE to Patients Earlier in Their Disease Course and Would Fulfill Post-Marketing Requirement From FDA—

BRIDGEWATER, N.J., Sept. 21, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's Supplemental New Drug Application (sNDA) for review of ARIKAYCE® (amikacin liposome inhalation suspension) for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen. In its communication to Insmed, the FDA granted Priority Review to the sNDA and set a target action date of January 28, 2027, under the Prescription Drug User Fee Act (PDUFA).

"The FDA's acceptance of this application marks a pivotal moment in our ambition to change the treatment paradigm for MAC lung disease," said Martina Flammer, M.D., MBA, Chief Medical Officer of Insmed. "MAC lung disease is progressive — the longer the infection persists, the greater the damage to lung tissue and the harder it becomes to treat. If full approval is granted, ARIKAYCE could reach patients earlier in their disease course, including those newly diagnosed or facing recurrent infections. We look forward to engaging with the FDA throughout the review process."

The FDA grants Priority Review to applications for medicines that, if approved, would provide a significant improvement in safety or effectiveness in the treatment of a serious condition.

ARIKAYCE received FDA accelerated approval in 2018 for refractory MAC lung disease and was the first product approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) — a pathway enacted under the 21st Century Cures Act to advance the development of antibacterial therapies for serious or life-threatening infections in patients with unmet needs.

The sNDA for full approval is supported by results from the Phase 3b ENCORE study, the pivotal study conducted to fulfill the post-marketing requirement associated with ARIKAYCE's accelerated approval. ENCORE met its primary endpoint and multiplicity-controlled secondary culture conversion endpoints, with ARIKAYCE plus multidrug therapy demonstrating statistically significant improvements in respiratory symptoms and culture conversion in adults with MAC lung disease compared to multidrug therapy alone.

Insmed also plans to review the ENCORE data with the Pharmaceuticals and Medical Devices Agency (PMDA) in the fourth quarter of 2026 to support potential label expansion in Japan.

About the Phase 3b ENCORE Study

ENCORE was a randomized, double-blind, placebo-controlled, Phase 3b study to evaluate the efficacy and safety of ARIKAYCE plus multidrug therapy in patients with a new occurrence of MAC lung infection who had not received antibiotics. The study enrolled 425 patients across 177 sites globally, including patients experiencing their first MAC infection (82.4%) or their second or third infection (17.6%). Patients were randomized 1:1 to receive once-daily ARIKAYCE plus multidrug therapy (azithromycin 250 mg + ethambutol 15 mg/kg; n=213) or placebo plus multidrug therapy (azithromycin 250 mg + ethambutol 15 mg/kg; n=212) for 12 months, followed by three months off treatment to assess durability of culture conversion.

The primary endpoint was change from baseline in Respiratory Symptom Score (RSS) at Month 13. The study met its primary endpoint and its multiplicity-controlled secondary culture conversion endpoints, demonstrating statistically significant improvements in respiratory symptoms and culture conversion. Patients treated with ARIKAYCE achieved earlier, greater and more durable culture conversion than those receiving comparator therapy, and the safety profile was consistent with the known safety profile of ARIKAYCE, with no new safety signals observed.

About MAC Lung Disease

Mycobacterium avium complex (MAC) lung disease is a rare and serious disease that can significantly increase morbidity and mortality. Patients with MAC lung disease can experience a range of symptoms that often worsen over time, including chronic cough, dyspnea, fatigue, fever, weight loss, and chest pain. In some cases, MAC lung disease can cause severe, even permanent damage to the lungs, and can be fatal. MAC lung disease is an emerging public health concern worldwide with significant unmet need.

About ARIKAYCE

ARIKAYCE® is approved in the United States as ARIKAYCE (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion, and in Japan as ARIKAYCE inhalation 590 mg (amikacin sulfate inhalation drug product). Current international treatment guidelines recommend the use of ARIKAYCE for appropriate patients. ARIKAYCE is a novel, inhaled, once-daily formulation of amikacin, an established antibiotic that was historically administered intravenously and associated with severe toxicity to hearing, balance, and kidney function. Insmed's proprietary PULMOVANCE™ liposomal technology enables the delivery of amikacin directly to the lungs, where liposomal amikacin is taken up by lung macrophages where the infection resides, while limiting systemic exposure. ARIKAYCE is administered once daily using the Lamira® Nebulizer System manufactured by PARI Pharma GmbH (PARI).

About PARI Pharma and the Lamira® Nebulizer System

ARIKAYCE is delivered by a novel inhalation device, the Lamira® Nebulizer System, developed by PARI. Lamira® is a quiet, portable nebulizer that enables efficient aerosolization of ARIKAYCE via a vibrating, perforated membrane. Based on PARI's 100-year history working with aerosols, PARI is dedicated to advancing inhalation therapies by developing innovative delivery platforms to improve patient care.

BOXED WARNING AND IMPORTANT SAFETY INFORMATION FOR ARIKAYCE IN THE U.S.

Hypersensitivity Pneumonitis has been reported with the use of ARIKAYCE in the clinical trials. Hypersensitivity pneumonitis (reported as allergic alveolitis, pneumonitis, interstitial lung disease, allergic reaction to ARIKAYCE) was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (3.1%) compared to patients treated with a background regimen alone (0%). Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids. If hypersensitivity pneumonitis occurs, discontinue ARIKAYCE and manage patients as medically appropriate.

Hemoptysis has been reported with the use of ARIKAYCE in the clinical trials. Hemoptysis was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (17.9%) compared to patients treated with a background regimen alone (12.5%). If hemoptysis occurs, manage patients as medically appropriate.

Bronchospasm has been reported with the use of ARIKAYCE in the clinical trials. Bronchospasm (reported as asthma, bronchial hyperreactivity, bronchospasm, dyspnea, dyspnea exertional, prolonged expiration, throat tightness, wheezing) was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (28.7%) compared to patients treated with a background regimen alone (10.7%). If bronchospasm occurs during the use of ARIKAYCE, treat patients as medically appropriate.

Exacerbations of underlying pulmonary disease has been reported with the use of ARIKAYCE in the clinical trials. Exacerbations of underlying pulmonary disease (reported as chronic obstructive pulmonary disease (COPD), infective exacerbation of COPD, infective exacerbation of bronchiectasis) have been reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (14.8%) compared to patients treated with background regimen alone (9.8%). If exacerbations of underlying pulmonary disease occur during the use of ARIKAYCE, treat patients as medically appropriate.

Anaphylaxis and Hypersensitivity Reactions: Serious and potentially life-threatening hypersensitivity reactions, including anaphylaxis, have been reported in patients taking ARIKAYCE. Signs and symptoms include acute onset of skin and mucosal tissue hypersensitivity reactions (hives, itching, flushing, swollen lips/tongue/uvula), respiratory difficulty (shortness of breath, wheezing, stridor, cough), gastrointestinal symptoms (nausea, vomiting, diarrhea, crampy abdominal pain), and cardiovascular signs and symptoms of anaphylaxis (tachycardia, low blood pressure, syncope, incontinence, dizziness). Before therapy with ARIKAYCE is instituted, evaluate for previous hypersensitivity reactions to aminoglycosides. If anaphylaxis or a hypersensitivity reaction occurs, discontinue ARIKAYCE and institute appropriate supportive measures.

Ototoxicity has been reported with the use of ARIKAYCE in the clinical trials. Ototoxicity (including deafness, dizziness, presyncope, tinnitus, and vertigo) were reported with a higher frequency in patients treated with ARIKAYCE plus background regimen (17%) compared to patients treated with background regimen alone (9.8%). This was primarily driven by tinnitus (7.6% in ARIKAYCE plus background regimen vs 0.9% in the background regimen alone arm) and dizziness (6.3% in ARIKAYCE plus background regimen vs 2.7% in the background regimen alone arm). Closely monitor patients with known or suspected auditory or vestibular dysfunction during treatment with ARIKAYCE. If ototoxicity occurs, manage patients as medically appropriate, including potentially discontinuing ARIKAYCE.

Nephrotoxicity was observed during the clinical trials of ARIKAYCE in patients with MAC lung disease but not at a higher frequency than background regimen alone. Nephrotoxicity has been associated with the aminoglycosides.

- Designation has the potential to accelerate development of current and future therapies built on Precigen's AdenoVerse platform

GERMANTOWN, Md., Sept. 21, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that the United States Food and Drug Administration (FDA) granted platform technology designation to the AdenoVerse® immunotherapeutic platform, which is used in the company's first commercial product, PAPZIMEOS®. The designation reflects the adaptability and potential of the platform to address a broad range of indications, including HPV-positive malignancies such as head and neck, cervical, anal, vulvar and vaginal cancers, as well as other diseases that may be targeted by future AdenoVerse-based product candidates.

FDA platform technology designation creates a pathway to leverage data generated for the development of PAPZIMEOS to potentially accelerate development of future AdenoVerse programs by utilizing existing manufacturing and preclinical knowledge to support future marketing applications and reduce duplication of development work. Platform technology designation provides opportunities for early FDA engagement, the ability to receive timely advice by having additional engagement with the FDA during development, and consideration of prior FDA manufacturing inspections for future applications.

To qualify for the platform technology designation, a platform must already be used in an FDA-approved product and the available evidence must demonstrate that it is well characterized, reproducible and has the potential to be adaptable across multiple products without compromising quality, manufacturing or safety. In granting this designation, the FDA determined that the AdenoVerse platform can be applied consistently across multiple products and is reasonably likely to generate meaningful efficiencies to the development or manufacturing process, and to the regulatory review process.

"This designation has the potential to accelerate the development of Precigen's broader AdenoVerse portfolio by allowing us to build on the technology established through PAPZIMEOS, which was approved by the FDA in August 2025. We expect the near-term impact will be especially meaningful for PRGN-2009 across multiple HPV-associated cancers, including cervical cancer and oropharyngeal squamous cell carcinoma. Importantly, the potential extends beyond PRGN-2009 to future AdenoVerse candidates such as those targeting additional cancers and other diseases," said Helen Sabzevari, PhD, President and CEO of Precigen. "We thank the FDA for recognizing the potential of the AdenoVerse platform. This designation will enable us to leverage prior data and engage with the FDA earlier and more frequently, creating opportunities to reduce duplicative work and bring greater speed, efficiency and predictability to the development of future AdenoVerse therapies."

AdenoVerse® Clinical Portfolio

Precigen's AdenoVerse portfolio includes a Phase 2 study of PRGN-2009 in combination with pembrolizumab in newly diagnosed patients with HPV-associated oropharyngeal squamous cell carcinoma (NCT05996523) and a Phase 2 study of PRGN-2009 in combination with pembrolizumab in patients with recurrent or metastatic cervical cancer (NCT06157151). The portfolio also includes PAPZIMEOS® (zopapogene imadenovec-drba; formerly PRGN-2012), which is the first FDA-approved therapy for the treatment of adults with recurrent respiratory papillomatosis (RRP). An open-label study evaluating the efficacy of redosing PAPZIMEOS in adults with RRP is currently enrolling (NCT06538480).

Precigen: Advancing Medicine with Precision®

Precigen (Nasdaq: PGEN) is a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn or YouTube.

Trademarks

Precigen, PAPZIMEOS, AdenoVerse, and Advancing Medicine with Precision are trademarks of Precigen and/or its affiliates. Other names may be trademarks of their respective owners.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what the Company expects. Examples of forward-looking statements include, among others, potential development efficiencies the platform technology designation may provide to accelerate the development of the Company's AdenoVerse clinical portfolio, potential benefits of the platform technology designation, information relating to the Company's business and business plans, the success of efforts to commercialize PAPZIMEOS® (zopapogene imadenovec-drba) for the treatment of recurrent respiratory papillomatosis (RRP) in adults, the Company's ability to successfully obtain foreign regulatory approvals for PAPZIMEOS, expectations about the safety and efficacy of PAPZIMEOS, the ability of PAPZIMEOS to treat RRP, the Company's future financial and operational results, and the Company's ability to commence clinical studies or complete ongoing clinical studies for the Company's clinical and pre-clinical stage candidates. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

Investor Contact:

Steven M. Harasym

Tel: +1 (202) 365-2563

[email protected]

Media Contact:

Donelle M. Gregory

[email protected]

SOURCE Precigen, Inc.

Share this article

James Sullivan Appointed Chief Financial Officer; Company Reaffirms Third Quarter Guidance

SAN JOSE, Calif., Sept. 21, 2026 /PRNewswire/ -- QuickLogic Corporation (NASDAQ: QUIK), a developer of embedded FPGA (eFPGA) Hard IP, Strategic Radiation Hardened and Antifuse FPGAs and ruggedized programmable logic solutions, today announced the appointment of James Sullivan as its new Senior Vice President of Finance and Chief Financial Officer, effective October 5, 2026. Sullivan replaces Elias Nader, who has resigned effective as of the close of business September 18, 2026, to pursue other opportunities.

"We thank Elias for his contributions over the past four years," said Brian Faith, CEO of QuickLogic. "The entire QuickLogic team remains focused on executing against our strategic priorities and advancing the growth opportunities before us in eFPGA IP, antifuse FPGA technology, and our Storefront business. Our previously announced third quarter 2026 guidance remains unchanged. We wish Elias the very best in his next chapter and appreciate his continued support during the transition."

"I am also pleased to welcome James Sullivan to QuickLogic," added Mr. Faith. "Jim is a seasoned semiconductor public company CFO with deep technical financial expertise and extensive experience helping innovative semiconductor companies achieve their growth objectives. His strong background across advanced wireless, aerospace, defense, and autonomous systems markets aligns well with QuickLogic's expanding opportunities in eFPGA IP, antifuse FPGA technology, and Storefront solutions. As we continue executing our strategy, Jim's track record building scalable financial and operational infrastructure will help position QuickLogic for long-term growth and value creation."

Mr. Sullivan most recently served as Chief Financial Officer for Peraso Inc., a publicly traded semiconductor company pioneering high-performance mmWave wireless technology, offering chipsets, modules, software and IP. Before joining Peraso, he spent 14 years as Chief Financial Officer of MoSys, Inc., a publicly traded fabless semiconductor company. He also held CFO roles at Apptera, Inc. and at 8x8, Inc., a publicly traded SAAS provider of VoIP and unified communication solutions. Sullivan began his career at PricewaterhouseCoopers LLP. He holds a B.S. in Accounting from New York University's Stern School of Business and is a certified public accountant.

Mr. Sullivan added, "I am excited to be joining QuickLogic at such a transformative time and look forward to partnering with the management team to continue our focus on financial discipline and thoughtful investment that will fuel our next chapter of growth, as we strive to build long-term shareholder value."

About QuickLogic

QuickLogic Corporation is a fabless semiconductor company specializing in eFPGA Hard IP, Strategic Radiation Hardened and Antifuse FPGAs and ruggedized programmable logic solutions. QuickLogic's unique approach combines cutting-edge technology with open-source tools to deliver highly customizable, low-power solutions for aerospace and defense, industrial, computing, and consumer markets. For more information, visit www.quicklogic.com.

QuickLogic and logo are registered trademarks of QuickLogic. All other trademarks are the property of their respective holders and should be treated as such.

SOURCE QuickLogic Corporation

Share this article

Breakthrough High Efficiency Fiber Technology Enables Uranium Adsorption from Seawater Rather Than Mined from Rock

LOS ANGELES, Sept. 21, 2026 /PRNewswire/ -- Fluxnium, Inc. (Fluxnium), a pioneer of domestic uranium supply adsorbed from seawater, today announced a $7 million seed round led by Congruent Ventures, with participation from Constellation Technology Ventures, the venture investing organization within Constellation (NASDAQ: CEG), the nation's largest producer of reliable and clean energy, and Active Impact Investments, Canada's largest climate technology seed fund. The funding catalyzes the commercialization of a new secure source of uranium, the critical mineral that underpins both the civilian nuclear fuel cycle and the defense supply chain. Proceeds will go towards further development, pilot testing and scale-up of Fluxnium's technology platform.

The largest uranium supply on Earth is not underground; it is dissolved in the ocean. Seawater holds centuries' worth of supply for the global uranium market — roughly a thousand times more than all currently identified terrestrial deposits combined. The challenge is that dissolved uranium exists at very low concentrations. Fluxnium addresses this challenge through its proprietary high-surface-area fiber, recently developed with a leading U.S. national laboratory, that passively adsorbs uranium as seawater moves past it.

"The United States imports more than 90% of its uranium supply at a time when nuclear power is increasingly seen as a solution to growing demand for electricity driven by economic growth," said Jeff Green, CEO and Founder of Fluxnium. "Fluxnium is developing a new domestic and sustainable supply of uranium, passively adsorbed from seawater on proven offshore infrastructure — at a cost projected to compete with conventional mining, with no tailings or ground water concerns."

Fluxnium's fiber deploys on longline systems in open water — the same passive marine infrastructure proven by seaweed and mussel farms — then is retrieved, processed, and redeployed. With accelerating demand for nuclear power, plant operators are very interested in cost-competitive and sustainable fuel supply beyond uranium mining. Traditional uranium production projects can require significant time, capital investment and regulatory review before reaching commercial operation. Adsorption from seawater addresses those concerns, and the approach expands production by deploying additional fiber rather than developing a new mine.

"With the current uranium market dynamics, there is a new path to making the ocean one of the lowest-cost sources in the world," said Kevin Kopczynski, Partner at Congruent Ventures. "Congruent is excited to support Fluxnium as it unlocks the ocean's potential as a major contributor to a diverse and robust domestic nuclear fuel supply chain."

"Innovations that could expand domestic sources of uranium are important areas of research for the nuclear energy industry," said Jason Murphy, Vice President of Nuclear Fuels, Constellation. "Fluxnium's technology has the potential to broaden future fuel supply options and support growing demand for clean, reliable nuclear energy."

"With global nuclear power generation projected to increase 2.5X in the next 15 years, Fluxnium is the future of uranium supply with clean, lower cost ocean adsorption displacing the environmental damage from mining and tailings," said Tom Boddez, General Partner at Active Impact Investment. "We have strong conviction that Jeff and co-founder Jim McDermott, with their prior successes taking hardtech ideas to commercial reality, are the ideal team to seize this opportunity."

About Fluxnium

Fluxnium is building a new domestic supply of uranium — adsorbed from seawater rather than mined from rock. Using high-efficiency adsorbent fiber developed with a leading U.S. national laboratory, Fluxnium passively adsorbs uranium already dissolved in seawater at a cost projected to match conventional mining. With the ocean containing centuries of uranium supply, capacity grows by deploying more fiber — becoming a production decision rather than a long-term capital investment for mine construction. And because there is no mine, there are no tailings or ground water concerns, which eliminates the slowest and most contested steps of conventional permitting. Deployed on the same infrastructure proven in offshore aquaculture, Fluxnium's mission is to make the ocean the lowest-cost source of uranium in the world. For more information, visit https://fluxnium.com

About Congruent Ventures

Congruent Ventures is an early-stage, climate-focused venture capital firm founded in 2017. The firm backs North American founders from formation through Series A across five sectors: Energy Abundance, Agriculture + Food, Industry + Efficiency, Mobility + Built Environment, and Resilience + Restoration. Congruent manages over $1B in AUM across three early-stage funds and one later-stage fund, and has backed 60+ companies to date. Learn more at congruentvc.com.

About Constellation Technology Ventures

Constellation Technology Ventures (CTV) is the venture investing organization within Constellation, the United States' largest producer of clean, carbon-free energy and a leading supplier of energy products and services to businesses, homes, community aggregations and public sector customers. CTV invests in companies exploring innovative energy technologies and business models, building a portfolio that represents a broad range of development stages and technology types. CTV's participation represents a venture investment in the continued development of Fluxnium's technology and does not constitute a fuel-purchase commitment at this time.

About Active Impact Investments

Active Impact Investments is Canada's largest climate tech seed fund, managing three funds and $180M in assets from Vancouver, British Columbia. We are helping build the future of production and consumption by investing in early-stage companies that solve the most urgent environmental challenges while achieving venture scale. We look for capital-efficient, market-ready businesses that deliver cheaper, better solutions with immediate customer ROI. Beyond capital, we dedicate our time to the areas founders need most: sales, talent and fundraising, supported by a global network of operators and investors. Active Impact is a Certified B Corp.

Media Contact

Jeff Green

CEO & Founder

SOURCE Fluxnium Inc.

Share this article

DALLAS, Sept. 21, 2026 /PRNewswire/ -- enCore Energy Corp. (NASDAQ, TSXV: EU) (the "Company" or "enCore"), America's Clean Energy Company™, announced today that the Company has engaged North Star Investor Relations Inc. ("North Star") to provide investor relations consulting services pursuant to a consulting agreement effective September 18, 2026 (the "Consulting Agreement"). North Star will support the Company's investor relations activities, including shareholder outreach, capital markets intelligence, media communications, and the coordination of press releases.

Under the Consulting Agreement, the Company will pay North Star a monthly cash retainer of CAD $10,000 for an initial term of one year. The Consulting Agreement may be renewed at the end of the initial term, to be mutually agreed upon between the Company and North Star, and it may be terminated by either party upon 30 days' prior written notice. North Star is owned by Graham Farrell and has an office at 130 King St. W #1900, Toronto, ON M5X 2A2 and can be reached at [email protected]. North Star and its principals are at arm's length to the Company and, to the knowledge of the Company, held no securities of the Company at the time the Consulting Agreement was executed.

The provision of services by North Star under the Consulting Agreement is subject to TSXV approval.

Distribution of Verdera Common Shares

As previously disclosed on September 15, 2026, the Company set a record date for its distribution of 35,000,000 common shares of Verdera Energy Corp. (the "Distribution Shares") as a special dividend on September 30, 2026, to shareholders of record on September 25, 2026. The pro rata distribution of the Distribution Shares will result in the Company's shareholders receiving approximately 0.18 of a Distribution Share for each common share of the Company, subject to adjustment on the record date.

The distribution is subject to the completion of all necessary filings with, and receipt of all approvals from, the Nasdaq Capital Market LLC and the TSX Venture Exchange.

About enCore Energy Corp.

enCore Energy Corp., America's Clean Energy Company™, is committed to providing clean, reliable, and affordable uranium to fuel the rapidly expanding U.S. nuclear energy needs. enCore's team is led by industry experts with extensive knowledge and experience in all aspects of uranium ISR operations and the nuclear fuel cycle. enCore exclusively uses ISR for uranium extraction, a minimally invasive, eco-friendly, and economically competitive mineral extraction technology co-developed by enCore's leadership.

Building on enCore's demonstrated and continuing success in South Texas, future projects in enCore's planned project pipeline include the expansion of Alta Mesa to include the Alta Mesa East property, the Dewey Burdock project in South Dakota, and the Gas Hills project in Wyoming. The Company holds other assets, including non-core assets and proprietary databases. enCore is committed to working with local communities and indigenous governments to create positive impacts from corporate projects.

For further information please contact:

William M. Sheriff

Executive Chair

972.333.2214

[email protected]

www.encoreuranium.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Cautionary Note Regarding Forward Looking Statements:

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities laws that are based on management's current expectations, assumptions and beliefs. Forward-looking statements can often be identified by such words as "anticipates," "will," "may," "expects," "plans," "believes," "intends," "estimates," "projects," "continue," "potential," and similar expressions or variations (including negative variations) of such words and phrases, or statements that certain actions, events or results "may," "could," or "will" be taken.

Forward-looking statements and information that are not statements of historical fact include, but are not limited to, any statements regarding future expectations, beliefs, goals or prospects and statements regarding the timing and completion of a distribution of the Distribution Shares to shareholders of the Company and should be considered forward-looking statements. All such forward-looking statements are not guarantees of future results and forward-looking statements are subject to important risk factors and uncertainties, many of which are beyond the Company's ability to control or predict, that could cause actual results to differ materially from those expressed in any forward-looking statement.

A number of important factors could cause actual results or events to differ materially from those indicated or implied by such forward-looking statements, including factors relating to forward-looking statements listed above which include risks as disclosed in the Company's filings on SEDAR+ and with the SEC, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, management discussion and analysis and annual information form. Should one or more of these risks materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. The Company assumes no obligation to update the information in this communication, except as required by law. Additional information identifying risks and uncertainties is contained in filings by the Company with the respective securities commissions which are available online at www.sec.gov and www.sedarplus.ca.

Forward-looking statements are provided for the purpose of providing information about the current expectations, beliefs and plans of management. Such statements may not be appropriate for other purposes and readers should not place undue reliance on these forward-looking statements, that speak only as of the date hereof, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

SOURCE enCore Energy Corp.

Share this article

JOHNSTON, Iowa and GHENT, Belgium, Sept. 21, 2026 /PRNewswire/ -- Vylor, the advanced seed and genetics company that will spin off from Corteva on October 1, 2026, and Rainbow Crops, a Belgium-based spin off from VIB, have announced a collaboration to advance new corn traits using artificial intelligence (AI) and multiplex gene editing, which enables scientists to edit multiple genes in a cell simultaneously.

Through the collaboration, both companies will use Rainbow Crops' AI-supported Trait Foundry™ technology to accelerate the development of corn hybrids that are more resilient to extreme weather, such as heat, drought, and floods. Rainbow Crops' platform will support Vylor's industry-leading expertise in gene editing. The companies expect the collaboration to deliver complex agronomic traits that use inputs more efficiently and, ultimately, increase yield to support farmer profitability.

"Rainbow Crops' AI-enabled multiplex gene editing capabilities will allow us to make hundreds of gene edits simultaneously, while validating performance in state-of-the-art phenotyping facilities as well as through field trials," said Mat Muller, who will lead Vylor Edge, Vylor's investment platform. "Genome editing is set to reimagine agriculture by creating plants that can withstand critical challenges, including disease and extreme weather. This partnership further cements Vylor's leadership in this emerging science by leveraging Rainbow Crops' proprietary, cutting-edge technology."

Rainbow Crops' Trait Foundry™ combines AI, multiplex genome editing, precision breeding, and automated phenotyping (high-throughput measurement of plant characteristics) to design, generate, and validate improved crop genetics faster and more precisely than traditional breeding approaches allow. The platform is designed to address traits controlled by multiple interacting genes, such as drought tolerance and plant vigor.

"Our early work in corn has been an important proof point for Rainbow Crops and has shown the potential of our Trait Foundry platform to accelerate the development of complex traits," said Giacomo Bastianelli, CEO and co-founder of Rainbow Crops. "We are thrilled to collaborate with Vylor, a global leader in advanced seed and genetics, to explore new opportunities for innovation in corn."

The collaboration comes at a pivotal moment for plant innovation in Europe, following the European Parliament's passage, on 17 June 2026, of legislation that allows plants developed through gene editing to be imported and cultivated across the European Union.

Corteva, through its Corteva Catalyst investment platform, participated in Rainbow Crops recently closed €9.7 million seed financing round. Upon the company's separation, this investment will become a part of the Vylor Edge portfolio.

About Vylor

Vylor is an advanced seed and genetics company that has, for more than a century, been focused on delivering groundbreaking innovation to farmers. Anchored in the agriculture industry's most elite germplasm and transformative biotech, Vylor leverages its scientific expertise to deliver next generation technology to help farmers around the world boost yields. With its expertise in advanced science, leading routes-to-market and an expanding licensing business, Vylor drives value and delivers growth for farmers, customers and shareholders – and in doing so, helps feed, fuel and clothe the world. More information at vylor.com.

About Rainbow Crops

Rainbow Crops is a next-generation agtech company developing climate-resilient, high-performing crop varieties through its proprietary Trait Foundry™ platform. By integrating multiplex genome editing, artificial intelligence, precision breeding, and automated phenotyping, Rainbow Crops enables the systematic engineering of complex agronomic traits. The company collaborates with seed and breeding partners to advance sustainable agriculture and global food security. Founded in 2025 as a spin-off from the VIB–UGent Center for Plant Systems Biology, Rainbow Crops builds on years of publicly supported research and operates within VIB's advanced research infrastructure.

Learn more at www.rainbowcrops.com

Cautionary Statement

This release contains certain estimates and forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like "may," "expects," "will," "aims," "believes," "intends," or other words of similar meaning. All statements that address expectations or projections about the future, including statements about the proposed spin-off of Vylor from Corteva (including its expected timing and completion), the parties' expectations related to regulatory matters, product development and commercialization, the Vylor-Rainbow Crops collaboration and its anticipated benefits, and the parties' product offerings and financial or sustainability performance, are forward-looking statements. No obligation to update or revise any forward-looking statement, except as required by applicable law, is hereby undertaken and any such obligation is specifically disclaimed. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements or other estimates is included in the "Risk Factors" sections of Corteva's Annual Report on Form 10-K, and as modified by subsequent reports on Form 10-Q and Current Reports on Form 8-K, and Vylor's Registration Statement on Form 10.

SOURCE Corteva Agriscience

Share this article

Exclusive agreement paves the way for CME FSPI baseball futures

CHICAGO, Sept. 21, 2026 /PRNewswire/ -- FutureSports, the independent index administrator transforming professional and college sports statistics into rules-based, benchmark financial indexes, today announced an agreement with Major League Baseball (MLB) to create first-of-their-kind indexes on baseball team performance. Under the agreement, MLB will provide FutureSports with Official League Data that the company will use to create new broad-based CME FutureSports Performance Indexes (FSPI) on each of the 30 MLB clubs.

The agreement paves the way for CME Group to list weekly, monthly and quarterly cash-settled futures contracts, pending regulatory review, based on the CME FSPI MLB benchmarks.

CME FSPI are designed to systematically measure the cumulative performance of teams in prominent sports leagues. The play-by-play benchmark indexes will provide hedging vehicles and investment opportunities.

Rhett Dinsdale, Co-Founder of FutureSports, said: "We're thrilled to collaborate with MLB to create indexes on America's beloved sport. The business of baseball has grown significantly over the years, and we aim to provide a new way for the industry participants to hedge their capital exposures."

FutureSports and CME Group are committed to maintaining the highest standards of integrity and transparency. CME FSPI are administered using transparent, rules-based methodologies derived from Official League Data, helping ensure that index values are determined objectively and independently. FutureSports and CME Group will work with MLB on integrity matters related to CME FSPI baseball futures contracts, establishing a framework to share information in a manner consistent with applicable law. MLB will have no involvement in the determination, calculation or governance of the indexes, which are the purview of FutureSports.

FutureSports and the National Hockey League (NHL) previously announced the creation of CME FSPI based on hockey team performance, and CME Group intends to launch futures contracts on the indexes on Sept. 28, pending regulatory review.

About FutureSports

Under development since 2022 and launched in 2026, Chicago-based FutureSports has created a proprietary index methodology for measuring on-field, on-ice and on-court performance for a range of professional sporting teams and athletes. Partnering with many of the most recognizable sports leagues and financial market participants, FutureSports transforms live, play-by-play statistical data into rules-based, benchmark indexes that may be referenced by exchange-listed financial products. The indexes are designed to serve the same benchmarking function as the leading equity, commodity and fixed income indexes utilized every day across major global exchanges to track performance and hedge risk in the financial markets. FutureSports administers the indexes independently, with formal governance, oversight and methodology change procedures designed to align with the International Organization of Securities Commissions (IOSCO) Principles for Financial Benchmarks. For more information, visit www.futuresports.com.

SOURCE FutureSports

Share this article

Refinancing includes completion of $500 million equity rights offering, $550 million Nordic bond issuance and new long-term Letter of Credit facility

HOUSTON, Sept. 21, 2026 /PRNewswire/ -- McDermott International, Ltd ("McDermott" or the "Company") today announced the successful completion of its comprehensive refinancing transaction, including a backstopped $500 million equity financing, a $550 million senior secured Nordic bond issuance and a new long-term letter of credit and guarantee facility.

The refinancing builds upon the Company's strong operational and financial performance, including consistent project execution and disciplined bidding. This platform for long-term growth positions McDermott to execute its high-quality global backlog, pursue disciplined growth opportunities and advance its long-term strategy.

"This refinancing reflects the continued support and confidence our shareholders, lenders and bond investors have shown in our strategy, performance and future," said Michael McKelvy, McDermott Chief Executive Officer and Chair of the Board of Directors. "We believe the successful completion of this transaction positions McDermott with the financial foundation to continue building on the momentum we've established through strong project delivery and a relentless focus on serving our customers."

The completed refinancing consists of:

- $500 million equity financing through a rights offering to existing shareholders, which was 97% subscribed by Class A ordinary shareholders and completed by the related backstop commitments,

- A $550 million senior secured bond issuance in the Nordic market due in 2031,

- A new long-term letter of credit and guarantee facility, and

- A revolving credit facility.

Collectively, these transactions are designed to extend McDermott's maturity profile, further deleverage the balance sheet and provide long-term financing certainty.

About McDermott

McDermott is a premier, fully-integrated provider of engineering and construction solutions to the energy industry. Our customers trust our technology-driven approach engineered to responsibly harness and transform global energy resources into the products the world needs. From concept to commissioning, McDermott's innovative expertise and capabilities advance the next generation of global energy infrastructure—empowering a brighter, more sustainable future for us all. Operating in over 30 countries, McDermott's locally-focused and globally-integrated resources include more than 30,000 employees, a diversified fleet of specialty marine construction vessels and fabrication facilities around the world. To learn more, visit www.mcdermott.com.

Forward-Looking Statements

McDermott cautions that statements in this communication which are forward-looking, and provide other than historical information, involve risks, contingencies and uncertainties. These forward-looking statements include, among other things, statements about the expected benefits achieved through the completion of the refinancing. Although we believe that the expectations reflected in those forward-looking statements are reasonable, we can give no assurance that those expectations will prove to have been correct. Those statements are made by using various underlying assumptions and are subject to numerous risks, contingencies and uncertainties, including, among others: adverse changes in the markets in which we operate or credit or capital markets; our inability to successfully execute on contracts in backlog; changes in project design or schedules; the availability of qualified personnel; changes in the terms, scope or timing of contracts, contract cancellations, change orders and other modifications and actions by our customers and other business counterparties; changes in industry norms; actions by lenders, other creditors, customers and other business counterparties of McDermott and adverse outcomes in legal or other dispute resolution proceedings. If one or more of these risks materialize, or if underlying assumptions prove incorrect, actual results may vary materially from those expected. You should not place undue reliance on forward-looking statements. This communication reflects the views of McDermott's management as of the date hereof. Except to the extent required by applicable law, McDermott undertakes no obligation to update or revise any forward-looking statement.

Contacts:

Global Media Relations

Reba Reid

+1 281 588 5636

[email protected]

SOURCE McDermott International, Ltd

Share this article

A New Episode of Advancements to Broadcast on Saturday, September 26 at 8:00 p.m. ET

Discover how new technologies, tools, and approaches are addressing some of the greatest challenges facing society today.

JUPITER, Fla., Sept. 21, 2026 /PRNewswire/ -- An upcoming episode of Advancements with Ted Danson is scheduled to broadcast on Saturday, September 26, 2026, at 8:00 pm ET. Tune in to Bloomberg Television to watch.

Across four featured segments, the program examines how organizations are responding to growing demands for infrastructure, sustainability, continuous healthcare, and more adaptable industrial systems. The episode opens with a look at the evolution of construction and megaproject delivery. As demand grows for semiconductor fabrication facilities, clean energy projects, advanced manufacturing, transportation, and other infrastructure, the construction industry faces pressure to deliver projects faster and at greater scale. Watch to discover how artificial intelligence, automation, project data, and other technologies are being applied to the construction industry and are empowering a new generation of skilled craft professionals, engineers, and project managers.

The program then turns to the challenge of making food packaging more recyclable. Packaging represents roughly one-third of municipal solid waste in the United States, while food packaging presents its own challenges, because of contamination, complex materials, and recycling systems that are not always equipped to process them. The segment examines how packaging design can influence recyclability. Industry experts explore approaches involving recyclable P.E.T. packaging, pad-less tray designs, and clearer consumer disposal information designed to support better recycling outcomes and a more circular materials economy.

Healthcare is the focus of the third segment, which examines the movement from episodic care toward more continuous care. While American healthcare provides highly advanced acute and specialty services, care is frequently organized around individual encounters, such as hospitalizations, physician visits, tests, and follow-ups. Learn about the clinical "white space" between those encounters and how remote monitoring, clinical intelligence, communication, and human decision-making can work together to provide greater visibility into a patient's health journey. The segment will share how continuous specialty care can extend beyond traditional healthcare settings and into the home and will include patient stories illustrating the potential impact of earlier intervention and ongoing support.

The episode concludes with an examination of modernizing industrial control systems. Learn why the demands of AI, advanced analytics, and cybersecurity are changing what manufacturers need from their automation systems. The show will educate about the limitations of traditional closed control architectures, including vendor lock-in and interoperability challenges, as it introduces Open Process Automation (OPA) as an approach based upon open, standards-based architectures. Viewers will see how the technology can allow hardware and software from different suppliers to work together, giving manufacturers greater flexibility to upgrade and adapt their systems over time.

This episode examines how industries are adapting established systems to meet rapidly changing demands. From construction sites and food packaging facilities to patients' homes and industrial plants, emerging technologies are being used alongside new operating models and human expertise to improve how complex systems function," said Dustin Schwarz, programming director for the Advancements series.

Featured segments in this episode include Bechtel, Lucid Corp, Streamcare Group, and Collaborative Systems Integration (CSI).

About Advancements:

Advancements is an information-based educational television series that explores recent developments taking place across several industries and economies. With a focus on some of the major innovations responsible for global progress today, the award-winning series goes behind-the-scenes to discover and share how technology and innovation continue to drive the world forward.

For more information, please visit

www.AdvancementsTV.com

or call 866-496-4065.

SOURCE Advancements

Share this article